Dixon Hubard Feinour & Brown’s AstraZeneca AZN Stock Holding History

Dixon Hubard Feinour & Brown’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$379K	Hold	2,866	–	–	0.05%	215
2022 Q1	$380K	Hold	2,866	–	–	0.04%	240
2021 Q4	$334K	Buy	2,866 +125	+5%	+$14.7K	0.03%	251
2021 Q3	$329K	Buy	2,741 +109	+4%	+$12.7K	0.07%	142
2021 Q2	$315K	Sell	2,632 -4,386	-62%	-$481K	0.07%	148
2021 Q1	$742K	Buy	7,018 +2,675	+62%	+$269K	0.09%	130
2020 Q4	$476K	Hold	4,343	–	–	0.12%	106
2020 Q3	$476K	Buy	4,343 +1,338	+45%	+$149K	0.12%	106
2020 Q2	$338K	Buy	3,005 +555	+23%	+$57.3K	0.09%	126
2020 Q1	$219K	Hold	2,450	–	–	0.07%	145
2019 Q4	$244K	Hold	2,450	–	–	0.06%	157
2019 Q3	$218K	Hold	2,450	–	–	0.06%	162
2019 Q2	$202K	Buy	+2,450	New	+$192K	0.06%	169
2015 Q2	–	Sell	-3,400	Closed	-$233K	–	187
2015 Q1	$233K	Sell	3,400 -64	-2%	-$4.45K	0.07%	174
2014 Q4	$244K	Hold	3,464	–	–	0.08%	169
2014 Q3	$247K	Hold	3,464	–	–	0.08%	164
2014 Q2	$257K	Hold	3,464	–	–	0.08%	161
2014 Q1	$225K	Buy	+3,464	New	+$224K	0.08%	172

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dixon Hubard Feinour & Brown's AZN Position: Q2 2022 in Review

Dixon Hubard Feinour & Brown held its AstraZeneca (AZN) position steady in Q2 2022 at 2,866 shares worth $379K. The position accounts for 0.05% of the portfolio, ranked #215.

Dixon Hubard Feinour & Brown first reported a position in AZN in Q1 2014 and has held it in 18 quarters since. The position peaked at $742K in Q1 2021. 1,016 funds tracked by Wall St. Rank hold AZN as of Q2 2022.

Dixon Hubard Feinour & Brown held 2,866 shares of AstraZeneca worth $379K as of Q2 2022.
Dixon Hubard Feinour & Brown left its AstraZeneca share count unchanged in Q2 2022.
AstraZeneca made up 0.05% of Dixon Hubard Feinour & Brown's portfolio in Q2 2022, its #215 holding.
Dixon Hubard Feinour & Brown first reported a position in AstraZeneca in Q1 2014 and has held it in 18 quarters since.
Dixon Hubard Feinour & Brown's AstraZeneca position peaked at $742K in Q1 2021.
1,016 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2022.

Based on Dixon Hubard Feinour & Brown's 13F filing for Q2 2022, filed 22 Jul 2022.